• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C

    2016-04-28 01:43:37LiLiChunYanGouJingYingLiRehmatullahAchakzaiandXiuHuiLiBeijingChina

    Li Li,Chun-Yan Gou,Jing-Ying Li,Rehmatullah Achakzai and Xiu-Hui LiBeijing,China

    ?

    Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C

    Li Li,Chun-Yan Gou,Jing-Ying Li,Rehmatullah Achakzai and Xiu-Hui Li
    Beijing,China

    BACKGROUND:The Barcelona Clinic Liver Cancer(BCLC)staging system for hepatocellular carcinoma(HCC)recommends transarterial chemoembolization(TACE)as the first line therapy for stage B patients and sorafenib treatment for stage C patients.However,stage C patients exhibit variations in terms of tumor burden,liver function,and extrahepatic metastasis,which could potentially affect disease outcome.Here,we assessed whether the Cancer of the Liver Italian Program(CLIP)scores can help identify stage C patients likely to benefit from TACE.

    METHODS:Out of 295 BCLC stage C HCC patients enrolled between January 2009 and December 2011,those with platelet counts >30×109cells/L,total bilirubin <51 μmoL/L,and an unobstructed main portal vein were scheduled for TACE(n=195).The remaining patients received best supportive care(BSC,n=100).All the patients were followed up for symptoms,performance status,and Child-Pugh classification scores every 4 weeks until death or December 2013.The prognosis of each group was evaluated by using the log-rank test and Cox-Mantel test.

    RESULTS:The median overall survival(OS)was 6 months [95% confidence interval(CI):4.64-7.36].The OS was 9 months for the TACE group and 4 months for the BSC group.The TACE group had a longer OS than the BSC subgroup for CLIP scores 0-2 [13 months(95% CI:8.55-17.45)vs 4 months(95% CI:0.00-10.96),P=0.001].No significant differences were found between the TACE and BSC groups for CLIP scores 3-5.The CLIP score and treatment methods were found to be independent prognostic factors.

    CONCLUSIONS:BCLC stage C HCC patients exhibit definite disease heterogeneity and can be reclassified by using the CLIP scoring system.Moreover,patients with CLIP scores 0-2 are likely to benefit from TACE.However,additional studies with long-term follow-up will be required to validate these findings.

    (Hepatobiliary Pancreat Dis Int 2016;15:152-157)

    KEY WORDS:hepatocellular carcinoma;

    BCLC staging system;

    CLIP scoring system;

    transarterial chemoembolization

    Author Affiliations:Department of Combined TCM and Western Medicine,Beijing You’an Hospital(Li L,Gou CY,Li JY and Li XH)and International School(Achakzai R),Capital Medical University,Beijing 100069,China Corresponding Author:Xiu-Hui Li,MD,Department of Combined TCM and Western Medicine,Beijing You’an Hospital,Capital Medical University,No.8,Xi Tou Tiao,You’anmen Wai,Fengtai District,Beijing 100069,China(Fax:+86-10-63296491;Email:lixiuhui@sohu.com)

    ? 2016,Hepatobiliary Pancreat Dis Int.All rights reserved.

    Published online February 24,2016.

    Introduction

    H epatocellular carcinoma(HCC)is the fifth most common cancer and the third leading cause of cancer-related deaths worldwide.[1,2]According to the practice guidelines of the American Association for the Study of Liver Diseases(AASLD)for HCC,the Barcelona Clinic Liver Cancer(BCLC)system is the only staging system that can match patient groups to therapies across the continuum of disease heterogeneity seen with HCC.[3,4]Based on the BCLC staging system,transarterial chemoembolization(TACE)is recommended as the first line non-curative therapy for patients with large or multifocal HCC without vascular invasion or extrahepatic metastasis(BCLC stage B),whereas sorafenib is recommended as first line therapy for advanced(BCLC stage C)HCC patients requiring liver function protection who are less likely to benefit from curative therapy or TACE.[5-7]

    However,sorafenib is not always available for some HCC patients due to financial limitations,especially in developing countries.In Asian countries,TACE has been widely used for patients with unresectable HCC,including those with portal vein thrombosis and extrahepatic metastasis,because of its good survival benefit and over-all safety for selected patients.[8-13]Tumor burden,liver function,portal vein invasion,and extrahepatic metastasis vary among BCLC stage C patients.This heterogeneity suggests different prognostic outcomes in these patients and the possibility that there are different strata of BCLC stage C patients with variable prognosis and requiring different optimal therapies.

    In this study,we analyzed the overall survival(OS)and prognostic factors of BCLC stage C patients with HCC and found that the Cancer of the Liver Italian Program(CLIP)scoring system could more accurately stratify the patients with different outcomes.[15]

    Methods

    Patients

    We enrolled 295 HCC patients who were initially classified into BCLC stage C between January 2009 and December 2011.The diagnosis of HCC was made according to the AASLD guidelines.[5]

    The inclusion criteria were:(1)Eastern Cooperative Oncology Group(ECOG)performance status of 1-2;(2)liver function reserve of class A-B on Child-Pugh classification;(3)Okuda stage 1-2;(4)portal vein tumor thrombosis and/or extrahepatic metastasis;and(5)patients treated with TACE or supportive treatment.Patients with a secondary malignancy or with severe organ function failure were excluded.OS was calculated from the date of enrollment till the date of death or December 31,2013.Gender,age,etiology,Child-Pugh class,CLIP score,tumor size,type,and extent,portal vein tumor thrombosis,extrahepatic metastasis,platelet count,serum aspartate aminotransferase(AST),and serum alpha-fetoprotein(AFP)level were included as baseline variables.

    The study protocol was approved by the Ethics Committee of Beijing You’an Hospital,Capital Medical University and adhered to the Declaration of Helsinki.Because of the retrospective nature of the study,written informed consent was waived off by the approval of the institutional review board.

    Treatment

    On the basis of our experience,patients with platelet count >30×109cells/L,total bilirubin <51 μmoL/L,and a main portal vein that was not completely obstructed by tumor thrombosis were scheduled for TACE.The patients were reevaluated after 3 to 4 weeks;in the interim,they were given symptomatic treatment as required.TACE would be repeated in the event of a residual tumor or if tumor recurrence was confirmed by computed tomography(CT)or magnetic resonance imaging(MRI)during follow-up.Patients who refused to undergo TACE or those who were not considered as suitable candidates for TACE were given symptomatic treatment or best supportive care(BSC).

    TACE

    Overall,195 patients underwent TACE.First,angiography was performed to identify the targeted feeding arteries of the tumor.The catheter was advanced to the hepatic artery and then to the lobar and segmental branches to facilitate maximum selectivity.A combination of chemotherapeutic agents and iodized oil was injected into the arteries,and a gelatin sponge was used to embolize the feeding artery.Doxorubicin(50 mg/m2)or 5-fluorouracil(500 mg/m2)was used as chemotherapeutic agent.The quantities of the iodized oil and sizes of the gelatin sponges used to embolize the tumors were decided by two senior interventional physicians at our center based on the tumor sizes.

    Follow-up

    The patients were followed up for symptoms,ECOG performance status,and Child-Pugh classification with a physical examination every 4 weeks.They underwent enhanced MRI and CT scanning every 4 to 8 weeks until death or the end point of follow-up,December 31,2013.

    Statistical analysis

    All data were analyzed with the SPSS statistical software(IBM SPSS Statistics 21).Disease-specific survival was analyzed using the Kaplan-Meier method.The logrank test was used to analyze differences in survival.Multivariate analysis was performed using the Cox proportional hazards model with forward stepwise selection.A P value of <0.05 was considered statistically significant.

    Results

    Baseline characteristics of TACE and no-TACE patient Of the 295 patients,195(66.1%)received TACE(TACE group)and 100(33.9%)received symptomatic treatment or BSC(BSC group).TACE was repeated in 91 of the 195 patients;the median session of TACE procedures per patient was 2(range 1-8).Baseline characteristics of the patients are shown in Table 1.Gender,age,etiology,tumor size,extent,metastasis,platelet count,and the levels of AST and AFP were not significantly different between the two groups(Table 1).The baseline Child-Pugh class,CLIP score,portosytemic shunt,and portal vein invasion status were significantly different between the two groups,with patients in the BSC group having a moreadvanced disease status compared with the TACE group.

    Table 1.Baseline variables of the patients with BCLC stage C HCC(n,%)

    Analysis of prognosis

    The median OS was 6 months [95% confidence interval(CI):4.64-7.36] for all patients(Fig.1).The 1- and 2-year OS rates were 32.9% and 12.8%,respectively(P=0.001).

    In the Cox regression test,univariate analysis showed that the median OS was significantly longer in the TACE group than in the BSC group(9 vs 4 months,respectively;P=0.001;Table 2,Fig.2).Additionally,OS was significantly correlated with CLIP score(OS,12 months and 5 months for score 0-2 and score 3-5,respectively,P=0.001;Table 2,Fig.3),extent of tumor(OS,8 months and 4 months for ≤50% and >50%,respectively,P=0.001),portal vein thrombosis(OS,4 months and 7 months for groups with and without portal vein thrombosis,respectively,P<0.001),Child-Pugh class(OS,9 months and 4 months for class A and B,respectively,P=0.001),and AFP level(OS,8 months and 5 months for <400 ng/mL and ≥400 ng/mL,respectively,P=0.035)(Table 2).

    Fig.1.Kaplan-Meier curve of patients with BCLC stage C HCC.The median OS was 6 months(95% confidence interval:4.64-7.36,n=295).

    Fig.2.Kaplan-Meier curves for different treatment subgroups.The overall survival in the TACE group(median OS:9 months,n=195)was significantly longer than in the BSC group(median OS:4 months,n=100).

    Multivariate analysis,excluding the influence of con-founding factors,identified both the treatment method and CLIP score as independent prognostic factors for longer OS(P=0.001 in both cases;Table 3).

    Of note,subgroup analyses showed that patients with CLIP scores of 0-2 obtained more benefit from TACE than from BSC(P=0.001);the median OS was 13 months(95% CI:8.55-17.45)and 4 months(95% CI:0.00-10.96)in the TACE and BSC groups,respectively(Table 4,Fig.4A).In patients with CLIP scores of 3-5,however,there was no significant difference between the TACE and BSC groups;the median OS was 5 months and 4 months respectively for the two groups(Table 4,Fig.4B).

    Table 2.Univariate analysis for patients survival with BCLC stage C HCC

    Table 3.Multivariate analysis for patients survival with BCLC stage C HCC

    Table 4.Patients survival in the subgroups

    Fig.3.Kaplan-Meier curves for patients of different CLIP score subgroups.The overall survival in the CLIP 0-2 group(median OS:12 months,n=106)was significantly longer than that in the CLIP 3-5 group(median OS:5 months,n=189).

    Fig.4.Kaplan-Meier curves for different treatment subgroups categorized on the basis of CLIP scores.A:Kaplan-Meier curves for different treatment subgroups in patients with CLIP scores 0-2.These patients derived more benefit from TACE(median OS:13 months,n=80)than from BSC case(median OS:4 months,n=26).B:Kaplan-Meier curves for different treatment subgroups in patients with CLIP scores of 3-5.In this patient population,there was no significant difference between TACE(median OS:5 months,n=115)and BSC subgroups(median OS:4 months,n=74).

    Complications

    The incidence of complications was 82.05%(n=160)in the TACE group.The most common treatment-related complications were fever,abdominal pain,or temporary liver function deterioration.Two(1.02%)patients with CLIP scores of 4 and 5 experienced an irreversible deterioration of liver function and died of liver failure approximately 1 and 2 months after TACE,respectively.

    Discussion

    While several staging systems have been developed for HCC,there is no consensus on a universal accepted and optimal staging system that best predicts prognosis in HCC patients.[15-17]The heterogeneity in prevalence and etiology of HCC in different populations results in the inaccuracy of one staging system used in a population different from where it was developed.[17]

    The BCLC staging broadly classifies nonsurgical HCC as stage B(intermediate)or stage C(advanced);BCLC stage C patients have symptomatic tumors(ECOG performance status test,1-2),portal vein tumor invasion,or extrahepatic spread.[4]However,BCLC stage C HCC is known to include a heterogeneous group of patients with heterogeneous prognosis.[18]Patients in our study also showed heterogeneity in several baseline characteristics such as Child-Pugh class,CLIP score,portosystemic shunt,and portal vein invasion status,while other variables such as tumor size,extent,metastasis,and AFP levels were similar between the two study groups.

    While the BCLC staging classification recommends sorafenib as the first line therapy for BCLC stage C patients,[5-7]access to sorafenib is often limited in developing countries and TACE has been recommended and widely used as palliative therapy in China[19]and other Asian countries.[8-13]Studies[11-13]have shown that TACE provides good survival benefit and overall safety for selected patients with advanced HCC.Our study also showed a significantly longer overall survival(median OS,13 months)in patients treated with TACE compared with those treated with BSC(median OS,4 months).These results support TACE as a treatment strategy in advanced-stage HCC.

    Studies[20-23]have identified different prognostic factors for overall survival in BCLC stage C HCC patients.An Austrian study identified Child-Pugh class as the only independent prognostic factor in a group of advanced HCC patients treated by TACE or sorafenib.[20]A Japanese study[21]identified degree of liver damage,TNM stage,and AFP levels,and two Chinese studies[22,23]identified tumor lesion numbers,Child-Pugh class,metastasis,and portal vein invasion,as the independent prognostic factors in advanced HCC treated by TACE.In the present study,we identified that both the treatment method and CLIP score were independent prognostic factors for overall survival in the studied patients.Patients with CLIP 0-2 tumors had a longer OS than those with CLIP 3-5 tumors.Our results suggested that a CLIP score of 0-2 corresponds to better outcome than a higher score,and patients with a low CLIP score may still benefit from active therapy.

    Careful patient selection is known to be crucial for the success of TACE.[20]We found that TACE treatment significantly improved the OS in CLIP 0-2 patients compared with those with higher CLIP scores.Our findings supported that BCLC stage C patients have disease heterogeneity and could be further classified into different strata according to outcomes.Thus,the CLIP scoring system can be used as a useful tool to stratify patients with BCLC stage C HCC.CLIP classification is easy to perform;it considers Child-Pugh class,tumor morphological type,tumor extent,portal vein invasion,and serum AFP levels.CLIP classification thus inherently includes several independent prognostic determinants of HCC and has been shown to possess a higher predictive power than the Okuda classification.[15,24]Our findings also confirm that TACE is an effective therapy for BCLC stage C patients with a CLIP score of 0-2.[16]In this study,we identified the subgroup that could get the maximum benefit from TACE among BCLC stage C HCC patients.Further,TACE related complications observed in this study were comparable to that observed in previous studies suggesting that TACE is generally safe for patients even with advanced HCC.[11,25]

    The main limitations of our study are its retrospective nature and the fact that environmental factors,such as socioeconomic status and alcohol abuse,which affect the prognosis of HCC,were not taken into consideration.Moreover,the results of this study represent the outcomes of a single center in China and may not be universally applicable.

    In conclusion,BCLC stage C patients have disease heterogeneity and can be reclassified using the CLIP scoring system.Patients with CLIP scores 0-2 tend to have better overall survival and are better candidates for TACE.Future studies involving a randomized prospective design and longer follow-up durations are needed to verify whether implementation of different treatment modalities on the basis of CLIP scores result in overall improvement.The CLIP score may also be explored as a tool to identify patients with advanced HCC in clinical trials.

    Contributors:LXH proposed the study.LL and GCY performed the research and wrote the first draft.LJY and AR collected andanalyzed the data.All authors contributed to the design and interpretation of the study and to further drafts.LXH is the guarantor.Funding:This study was supported by grants from You’an Liver disease/AIDS funding(2011),and the National Science &Technology Pillar Program during the 12th Five-year Plan Period(2013BAI13B04).

    Ethical approval:The study protocol was approved by the Ethics Committee of Beijing You’an Hospital,Capital Medical University and adhered to the Declaration of Helsinki.

    Competing interest:No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

    References

    1 Parkin DM.Global cancer statistics in the year 2000.Lancet Oncol 2001;2:533-543.

    2 El-Serag HB,Rudolph KL.Hepatocellular carcinoma:epidemiology and molecular carcinogenesis.Gastroenterology 2007;132:2557-2576.

    3 Bruix J,Sherman M;Practice Guidelines Committee,American Association for the Study of Liver Diseases.Management of hepatocellular carcinoma.Hepatology 2005;42:1208-1236.

    4 Llovet JM,Brú C,Bruix J.Prognosis of hepatocellular carcinoma:the BCLC staging classification.Semin Liver Dis 1999;19:329-338.

    5 Bruix J,Sherman M;American Association for the Study of Liver Diseases.Management of hepatocellular carcinoma:an update.Hepatology 2011;53:1020-1022.

    6 Bruix J,Llovet JM.Prognostic prediction and treatment strategy in hepatocellular carcinoma.Hepatology 2002;35:519-524.

    7 Heng-jun G,Yao-jun Z,Min-shan C,Mei-xian C,Jun-ting H,Li X,et al.Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma.Liver Int 2014;34:612-620.

    8 Luo J,Guo RP,Lai EC,Zhang YJ,Lau WY,Chen MS,et al.Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis:a prospective comparative study.Ann Surg Oncol 2011;18:413-420.

    9 Xue TC,Xie XY,Zhang L,Yin X,Zhang BH,Ren ZG.Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus:a meta-analysis.BMC Gastroenterol 2013;13:60.

    10 Niu ZJ,Ma YL,Kang P,Ou SQ,Meng ZB,Li ZK,et al.Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus:using a new classification.Med Oncol 2012;29:2992-2997.

    11 Lee HS,Kim JS,Choi IJ,Chung JW,Park JH,Kim CY.The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction.A prospective controlled study.Cancer 1997;79:2087-2094.

    12 Kim KM,Kim JH,Park IS,Ko GY,Yoon HK,Sung KB,et al.Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion.J Gastroenterol Hepatol 2009;24:806-814.

    13 Yoo DJ,Kim KM,Jin YJ,Shim JH,Ko GY,Yoon HK,et al.Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma:does transarterial chemoembolization improve survival in these patients? J Gastroenterol Hepatol 2011;26:145-154.

    14 The Cancer of the Liver Italian Progran(CLIP)Investigators.A new prognostic system for hepatocellular carcinoma:a retrospective study of 435 patients:the Cancer of the Liver Italian Program(CLIP)investigators.Hepatology 1998;28:751-755.

    15 Huitzil-Melendez FD,Capanu M,O’Reilly EM,Duffy A,Gansukh B,Saltz LL,et al.Advanced hepatocellular carcinoma:which staging systems best predict prognosis? J Clin Oncol 2010;28:2889-2895.

    16 Farinati F,Rinaldi M,Gianni S,Naccarato R.How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system.Cancer 2000;89:2266-2273.

    17 Italian Association for the Study of the Liver(AISF);AISF Expert Panel;AISF Coordinating Committee,Bolondi L,Cillo U,Colombo M,et al.Position paper of the Italian Association for the Study of the Liver(AISF):the multidisciplinary clinical approach to hepatocellular carcinoma.Dig Liver Dis 2013;45:712-723.

    18 Llovet JM,Di Bisceglie AM,Bruix J,Kramer BS,Lencioni R,Zhu AX,et al.Design and endpoints of clinical trials in hepatocellular carcinoma.J Natl Cancer Inst 2008;100:698-711.

    19 China MoHotPsRo.Diagnosis,management,and treatment of hepatocellular carcinoma(V2011).J Clinical Hepatol 2011;11:1141-1159.

    20 Pinter M,Hucke F,Graziadei I,Vogel W,Maieron A,K?nigsberg R,et al.Advanced-stage hepatocellular carcinoma:transarterial chemoembolization versus sorafenib.Radiology 2012;263:590-599.

    21 Takayasu K,Arii S,Ikai I,Omata M,Okita K,Ichida T,et al.Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.Gastroenterology 2006;131:461-469.

    22 Liu L,Zhang C,Zhao Y,Qi X,Chen H,Bai W,et al.Transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis:prognostic factors in a single-center study of 188 patients.Biomed Res Int 2014;2014:194278.

    23 Xiao J,Li G,Lin S,He K,Lai H,Mo X,et al.Prognostic factors of hepatocellular carcinoma patients treated by transarterial chemoembolization.Int J Clin Exp Pathol 2014;7:1114-1123.

    24 Okuda K,Ohtsuki T,Obata H,Tomimatsu M,Okazaki N,Haregawwa H,et al.Natural history of hepatocellular carcinoma and prognosis in relation to treatment.Cancer 1985;56:918-928.

    25 Kim JH,Yoon HK,Kim SY,Kim KM,Ko GY,Gwon DI,et al.Transcatheter arterial chemoembolization vs.chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis.Aliment Pharmacol Ther 2009;29:1291-1298.

    Received April 29,2015

    Accepted after revision December 8,2015

    doi:10.1016/S1499-3872(16)60070-X

    超碰97精品在线观看| 久久国产精品大桥未久av| av卡一久久| 男女高潮啪啪啪动态图| 免费久久久久久久精品成人欧美视频 | 2018国产大陆天天弄谢| 亚洲欧洲国产日韩| 黄片无遮挡物在线观看| av网站免费在线观看视频| 狠狠婷婷综合久久久久久88av| 伦理电影大哥的女人| 99国产综合亚洲精品| www.av在线官网国产| 亚洲av电影在线进入| 日本免费在线观看一区| 视频在线观看一区二区三区| 男女国产视频网站| 97精品久久久久久久久久精品| 免费少妇av软件| 黑丝袜美女国产一区| 日本与韩国留学比较| 视频区图区小说| 最黄视频免费看| 国产av码专区亚洲av| 国产又色又爽无遮挡免| 男人舔女人的私密视频| 黄网站色视频无遮挡免费观看| 久久99热6这里只有精品| 国产精品国产三级国产专区5o| 久久精品夜色国产| 韩国av在线不卡| 欧美 日韩 精品 国产| 久久久久久人妻| 丝袜喷水一区| 91成人精品电影| 国产淫语在线视频| 久久这里有精品视频免费| 久久这里只有精品19| 日韩成人av中文字幕在线观看| 少妇熟女欧美另类| 80岁老熟妇乱子伦牲交| 蜜臀久久99精品久久宅男| 一级片'在线观看视频| 最近手机中文字幕大全| 国产免费又黄又爽又色| 精品熟女少妇av免费看| 大片电影免费在线观看免费| 久久精品夜色国产| 精品人妻在线不人妻| 在线看a的网站| 爱豆传媒免费全集在线观看| 日本欧美国产在线视频| 欧美97在线视频| 精品熟女少妇av免费看| 777米奇影视久久| 国产精品嫩草影院av在线观看| 极品少妇高潮喷水抽搐| 男女下面插进去视频免费观看 | 国产精品久久久av美女十八| 国产av码专区亚洲av| 视频区图区小说| 视频中文字幕在线观看| 男人舔女人的私密视频| 欧美最新免费一区二区三区| 各种免费的搞黄视频| 国产在视频线精品| 男女无遮挡免费网站观看| 满18在线观看网站| 久久久精品94久久精品| 亚洲国产欧美日韩在线播放| 美女脱内裤让男人舔精品视频| 国产成人免费观看mmmm| 在线 av 中文字幕| 久热这里只有精品99| 伊人亚洲综合成人网| 日本猛色少妇xxxxx猛交久久| 中文字幕精品免费在线观看视频 | 国产精品欧美亚洲77777| 国产 精品1| 久久这里有精品视频免费| 男女边摸边吃奶| 久久久久人妻精品一区果冻| 欧美成人精品欧美一级黄| 亚洲国产日韩一区二区| 美女国产视频在线观看| 最近手机中文字幕大全| av视频免费观看在线观看| 久久久亚洲精品成人影院| 黑人猛操日本美女一级片| 一二三四在线观看免费中文在 | 高清av免费在线| a级毛片黄视频| 久久精品熟女亚洲av麻豆精品| 午夜福利网站1000一区二区三区| 国产成人av激情在线播放| 女的被弄到高潮叫床怎么办| 免费av不卡在线播放| 色婷婷av一区二区三区视频| 男人爽女人下面视频在线观看| 国产淫语在线视频| 国产精品一国产av| 久久久久久久精品精品| 中文字幕亚洲精品专区| 国产av精品麻豆| 中国三级夫妇交换| 久久久久国产精品人妻一区二区| 捣出白浆h1v1| 七月丁香在线播放| 午夜激情av网站| 久久久欧美国产精品| 午夜av观看不卡| 国精品久久久久久国模美| 免费黄网站久久成人精品| 亚洲成色77777| 国产成人免费观看mmmm| 一边摸一边做爽爽视频免费| 国产淫语在线视频| 满18在线观看网站| 久久热在线av| 国产欧美日韩一区二区三区在线| 熟女av电影| 久久精品人人爽人人爽视色| 少妇人妻 视频| 一级毛片电影观看| 久久精品久久久久久久性| 成年人免费黄色播放视频| 国产极品粉嫩免费观看在线| 99久国产av精品国产电影| 男人添女人高潮全过程视频| 人成视频在线观看免费观看| 久久热在线av| av在线老鸭窝| 免费高清在线观看视频在线观看| 99久久综合免费| videos熟女内射| 欧美精品一区二区大全| 精品第一国产精品| 午夜福利视频在线观看免费| freevideosex欧美| 精品少妇内射三级| 午夜免费观看性视频| 黄片无遮挡物在线观看| 国产精品久久久久成人av| 亚洲精品久久成人aⅴ小说| 亚洲一区二区三区欧美精品| 91在线精品国自产拍蜜月| 日韩制服丝袜自拍偷拍| 伊人亚洲综合成人网| 国产精品女同一区二区软件| 涩涩av久久男人的天堂| 2022亚洲国产成人精品| 2018国产大陆天天弄谢| 日本欧美国产在线视频| 在线观看www视频免费| 高清毛片免费看| 久久精品国产鲁丝片午夜精品| 亚洲第一av免费看| 中国美白少妇内射xxxbb| 美女脱内裤让男人舔精品视频| 香蕉国产在线看| av免费在线看不卡| 亚洲精品久久午夜乱码| 亚洲综合精品二区| 亚洲国产欧美日韩在线播放| 免费在线观看完整版高清| 在线天堂最新版资源| 一区二区三区精品91| 桃花免费在线播放| 美女福利国产在线| 精品视频人人做人人爽| 亚洲,欧美,日韩| 少妇人妻久久综合中文| 精品一区二区三区视频在线| 久久久久国产网址| 国产男女内射视频| 国产爽快片一区二区三区| 午夜福利在线观看免费完整高清在| 91久久精品国产一区二区三区| 亚洲精品456在线播放app| 精品国产一区二区三区久久久樱花| 一级片'在线观看视频| 另类精品久久| 国产男女超爽视频在线观看| 九色成人免费人妻av| 激情视频va一区二区三区| 亚洲中文av在线| 国产极品粉嫩免费观看在线| 美女国产高潮福利片在线看| 国产成人精品福利久久| 精品午夜福利在线看| 国产亚洲一区二区精品| 国产福利在线免费观看视频| 一二三四中文在线观看免费高清| 国产淫语在线视频| 一区在线观看完整版| 精品久久久精品久久久| 国产av一区二区精品久久| 制服诱惑二区| 热99国产精品久久久久久7| 少妇的逼水好多| 欧美bdsm另类| 亚洲精品第二区| 少妇高潮的动态图| 欧美少妇被猛烈插入视频| 欧美成人精品欧美一级黄| 在线看a的网站| 日本av手机在线免费观看| 国产亚洲av片在线观看秒播厂| 国产女主播在线喷水免费视频网站| xxxhd国产人妻xxx| 久久精品aⅴ一区二区三区四区 | 大片电影免费在线观看免费| 黄色 视频免费看| 成人亚洲欧美一区二区av| 国国产精品蜜臀av免费| 国产日韩欧美亚洲二区| 一区在线观看完整版| 久久国内精品自在自线图片| 九草在线视频观看| 丰满迷人的少妇在线观看| 精品亚洲成国产av| 免费观看在线日韩| 丝袜美足系列| 欧美日本中文国产一区发布| www.熟女人妻精品国产 | 一边亲一边摸免费视频| 国产成人欧美| 视频在线观看一区二区三区| www日本在线高清视频| 久久av网站| 99热国产这里只有精品6| 国产老妇伦熟女老妇高清| 国产在线免费精品| 免费av中文字幕在线| 内地一区二区视频在线| 国产精品 国内视频| 一二三四中文在线观看免费高清| 国产毛片在线视频| 精品久久国产蜜桃| 国产日韩欧美在线精品| 国产 一区精品| 亚洲四区av| 高清视频免费观看一区二区| 午夜久久久在线观看| 天天躁夜夜躁狠狠躁躁| 汤姆久久久久久久影院中文字幕| 在线 av 中文字幕| 一级毛片黄色毛片免费观看视频| 国精品久久久久久国模美| 考比视频在线观看| 亚洲成国产人片在线观看| 超碰97精品在线观看| 国产免费一级a男人的天堂| 午夜福利视频精品| 日韩,欧美,国产一区二区三区| 国产精品三级大全| 成人综合一区亚洲| 国产成人免费观看mmmm| 99久久人妻综合| 日韩一本色道免费dvd| 精品久久久精品久久久| 国产一区二区激情短视频 | 国产亚洲一区二区精品| 日韩人妻精品一区2区三区| 午夜91福利影院| 人妻一区二区av| 在线观看三级黄色| 久久精品国产a三级三级三级| 只有这里有精品99| 久久人人爽人人片av| 日本-黄色视频高清免费观看| 精品少妇久久久久久888优播| 成人午夜精彩视频在线观看| 精品午夜福利在线看| 高清毛片免费看| av播播在线观看一区| 久久久久精品性色| 天堂中文最新版在线下载| 卡戴珊不雅视频在线播放| 少妇的逼水好多| 免费不卡的大黄色大毛片视频在线观看| 亚洲av综合色区一区| 纵有疾风起免费观看全集完整版| 精品卡一卡二卡四卡免费| 免费在线观看完整版高清| 亚洲内射少妇av| 国产亚洲av片在线观看秒播厂| 26uuu在线亚洲综合色| 亚洲五月色婷婷综合| 国产精品久久久久久久电影| 亚洲成人手机| 亚洲久久久国产精品| 丰满乱子伦码专区| 日本欧美视频一区| 精品久久蜜臀av无| 国产精品久久久av美女十八| 亚洲伊人久久精品综合| 在线亚洲精品国产二区图片欧美| 婷婷色综合大香蕉| 婷婷成人精品国产| 欧美日韩成人在线一区二区| 97精品久久久久久久久久精品| 亚洲欧美一区二区三区黑人 | 国产欧美日韩一区二区三区在线| av.在线天堂| 免费av中文字幕在线| 9热在线视频观看99| 涩涩av久久男人的天堂| 香蕉丝袜av| 免费av中文字幕在线| 飞空精品影院首页| 精品国产露脸久久av麻豆| 一级a做视频免费观看| 婷婷色av中文字幕| 久久国产精品大桥未久av| 一边亲一边摸免费视频| 99热这里只有是精品在线观看| 免费大片黄手机在线观看| 国产精品国产三级国产av玫瑰| 下体分泌物呈黄色| 久久久欧美国产精品| 人人妻人人澡人人看| 欧美 亚洲 国产 日韩一| 秋霞伦理黄片| 日本色播在线视频| 男人爽女人下面视频在线观看| 全区人妻精品视频| 又黄又粗又硬又大视频| 人人妻人人添人人爽欧美一区卜| 精品人妻在线不人妻| 一级片'在线观看视频| 国产精品麻豆人妻色哟哟久久| 免费在线观看黄色视频的| 国产亚洲一区二区精品| 91aial.com中文字幕在线观看| 亚洲人与动物交配视频| 久久99一区二区三区| 性色avwww在线观看| 亚洲成色77777| 久久 成人 亚洲| 一本一本久久a久久精品综合妖精 国产伦在线观看视频一区 | 日韩中文字幕视频在线看片| 久久久a久久爽久久v久久| 国产成人91sexporn| 乱人伦中国视频| 成人国产麻豆网| 亚洲国产欧美日韩在线播放| 看非洲黑人一级黄片| 飞空精品影院首页| 最新中文字幕久久久久| 国产69精品久久久久777片| 日韩av在线免费看完整版不卡| 久久精品国产综合久久久 | 性色avwww在线观看| 老司机影院毛片| 18禁在线无遮挡免费观看视频| 黄色配什么色好看| 黄片播放在线免费| 看免费成人av毛片| 中文字幕av电影在线播放| 在线天堂中文资源库| 日本爱情动作片www.在线观看| 精品一品国产午夜福利视频| 国产男女内射视频| 久久婷婷青草| 多毛熟女@视频| 日韩欧美一区视频在线观看| 国产精品欧美亚洲77777| 久久精品aⅴ一区二区三区四区 | 国产1区2区3区精品| 免费大片黄手机在线观看| av国产精品久久久久影院| 亚洲精品美女久久av网站| 国产综合精华液| 欧美人与善性xxx| 亚洲国产精品一区三区| 亚洲成av片中文字幕在线观看 | 又黄又粗又硬又大视频| 高清黄色对白视频在线免费看| 又黄又粗又硬又大视频| 亚洲精品aⅴ在线观看| 下体分泌物呈黄色| 婷婷色麻豆天堂久久| 久久久久国产精品人妻一区二区| 大香蕉久久成人网| 女的被弄到高潮叫床怎么办| 亚洲国产av新网站| 国产亚洲av片在线观看秒播厂| 亚洲精品乱久久久久久| 精品一品国产午夜福利视频| 搡老乐熟女国产| 亚洲国产精品999| 青春草亚洲视频在线观看| kizo精华| 久久精品久久精品一区二区三区| 成人亚洲精品一区在线观看| 午夜91福利影院| 中文字幕另类日韩欧美亚洲嫩草| 亚洲av免费高清在线观看| 国产免费一级a男人的天堂| 欧美日韩av久久| 美女大奶头黄色视频| 亚洲精品国产av成人精品| 永久网站在线| 97精品久久久久久久久久精品| 国产精品国产三级专区第一集| 韩国av在线不卡| 中文欧美无线码| 啦啦啦啦在线视频资源| 午夜av观看不卡| 中文字幕制服av| 日韩制服骚丝袜av| 国产又爽黄色视频| 欧美精品av麻豆av| 成人午夜精彩视频在线观看| 天堂8中文在线网| 精品人妻熟女毛片av久久网站| 久久99热这里只频精品6学生| 捣出白浆h1v1| 咕卡用的链子| 亚洲av欧美aⅴ国产| 亚洲四区av| 久久久久久久久久久久大奶| 侵犯人妻中文字幕一二三四区| 日本与韩国留学比较| 如何舔出高潮| 桃花免费在线播放| 男人添女人高潮全过程视频| 亚洲内射少妇av| 午夜视频国产福利| 亚洲情色 制服丝袜| 亚洲精品美女久久久久99蜜臀 | 中文天堂在线官网| 欧美丝袜亚洲另类| 亚洲国产av影院在线观看| 亚洲国产毛片av蜜桃av| 男女国产视频网站| 欧美+日韩+精品| 国产视频首页在线观看| 欧美激情 高清一区二区三区| 少妇的逼好多水| 十八禁高潮呻吟视频| 一本—道久久a久久精品蜜桃钙片| 国产日韩欧美在线精品| 久久影院123| 看免费成人av毛片| 99久久精品国产国产毛片| 国产永久视频网站| 国产精品国产三级国产专区5o| 国产男人的电影天堂91| 一级爰片在线观看| 国产片内射在线| 国产毛片在线视频| 9191精品国产免费久久| 欧美精品人与动牲交sv欧美| 丰满饥渴人妻一区二区三| 日本午夜av视频| 国产日韩欧美亚洲二区| 久久久精品94久久精品| 免费大片黄手机在线观看| 美国免费a级毛片| 美女大奶头黄色视频| 欧美3d第一页| 亚洲av.av天堂| 国产色婷婷99| 国产日韩一区二区三区精品不卡| 一本一本久久a久久精品综合妖精 国产伦在线观看视频一区 | 最后的刺客免费高清国语| 亚洲欧美一区二区三区黑人 | 男人舔女人的私密视频| 男人操女人黄网站| 精品国产国语对白av| 国产午夜精品一二区理论片| 18禁裸乳无遮挡动漫免费视频| 亚洲精品一区蜜桃| 国产国语露脸激情在线看| 18禁观看日本| 欧美精品一区二区免费开放| 日韩一区二区三区影片| 国产 精品1| 色94色欧美一区二区| 国产亚洲最大av| 国产色爽女视频免费观看| 日日撸夜夜添| 中文字幕免费在线视频6| 欧美精品一区二区免费开放| 人妻系列 视频| 只有这里有精品99| 少妇 在线观看| av网站免费在线观看视频| av女优亚洲男人天堂| 高清黄色对白视频在线免费看| 女性被躁到高潮视频| 男女免费视频国产| 午夜福利影视在线免费观看| 99国产综合亚洲精品| 国语对白做爰xxxⅹ性视频网站| videosex国产| 精品少妇内射三级| 亚洲人成77777在线视频| 成人无遮挡网站| 国产精品一区二区在线观看99| 日本爱情动作片www.在线观看| 97超碰精品成人国产| 久久人人爽av亚洲精品天堂| 日本黄色日本黄色录像| 欧美国产精品va在线观看不卡| 精品国产露脸久久av麻豆| 亚洲五月色婷婷综合| 免费播放大片免费观看视频在线观看| tube8黄色片| 男女高潮啪啪啪动态图| 亚洲成色77777| 日韩 亚洲 欧美在线| 日本午夜av视频| 日本欧美视频一区| 久久精品久久精品一区二区三区| 寂寞人妻少妇视频99o| 成人二区视频| 777米奇影视久久| 精品人妻在线不人妻| 美女xxoo啪啪120秒动态图| 尾随美女入室| 亚洲欧美日韩卡通动漫| 久久女婷五月综合色啪小说| 一本久久精品| 国产女主播在线喷水免费视频网站| 国产亚洲最大av| 一级黄片播放器| 久久99蜜桃精品久久| 999精品在线视频| 国产成人91sexporn| 新久久久久国产一级毛片| 国产成人精品婷婷| 日韩一区二区三区影片| 日本午夜av视频| 国产爽快片一区二区三区| 色吧在线观看| 午夜视频国产福利| 亚洲av电影在线观看一区二区三区| 考比视频在线观看| 在线观看美女被高潮喷水网站| av电影中文网址| 精品亚洲成国产av| 高清av免费在线| 亚洲人成网站在线观看播放| 黄片播放在线免费| 国产一区二区在线观看av| 国产1区2区3区精品| 夫妻性生交免费视频一级片| 欧美国产精品一级二级三级| 在线精品无人区一区二区三| 久久国产亚洲av麻豆专区| 99精国产麻豆久久婷婷| 久久国内精品自在自线图片| av网站免费在线观看视频| 麻豆精品久久久久久蜜桃| 欧美日韩精品成人综合77777| 18禁观看日本| 国产成人免费观看mmmm| 日韩电影二区| 国产亚洲最大av| 免费看光身美女| 精品卡一卡二卡四卡免费| 亚洲欧美精品自产自拍| 一二三四在线观看免费中文在 | 2018国产大陆天天弄谢| 亚洲第一av免费看| 一级a做视频免费观看| 免费播放大片免费观看视频在线观看| 黄片无遮挡物在线观看| 婷婷成人精品国产| 精品熟女少妇av免费看| 9热在线视频观看99| 在线观看免费日韩欧美大片| 国产欧美日韩综合在线一区二区| 午夜精品国产一区二区电影| 亚洲伊人久久精品综合| 日韩一区二区视频免费看| 久久热在线av| 国产欧美亚洲国产| 黑人欧美特级aaaaaa片| 人人妻人人澡人人爽人人夜夜| 婷婷色综合www| 国产黄色免费在线视频| 丝袜在线中文字幕| 日日撸夜夜添| 久久久久久久亚洲中文字幕| 亚洲欧洲日产国产| 高清视频免费观看一区二区| 在线观看免费高清a一片| 国产成人精品无人区| a级毛色黄片| 日本wwww免费看| 欧美精品高潮呻吟av久久| 欧美精品av麻豆av| 黑丝袜美女国产一区| 亚洲精品成人av观看孕妇| 精品国产一区二区久久| 午夜福利乱码中文字幕| 综合色丁香网| 一级毛片黄色毛片免费观看视频| 97精品久久久久久久久久精品| 五月伊人婷婷丁香| 久久热在线av| 国产亚洲av片在线观看秒播厂| 久久久国产一区二区| 午夜视频国产福利| 国产视频首页在线观看| 欧美日本中文国产一区发布| 王馨瑶露胸无遮挡在线观看| 精品福利永久在线观看| a级毛色黄片| 日本wwww免费看| 青春草视频在线免费观看|